Henry Lees-Buckley – Chief Executive Officer of Sativa Group PLC, is a seasoned corporate executive, with extensive experience of leading companies in the public markets.
Henry was previously CEO of Uni-Select [TSX:UNS], a Canadian TSX quoted company, with operations in the UK, Canada and the USA. Prior to that, he was a senior global executive and officer in the USA and Canada for W.W. Grainger, a US$15 billion Fortune 500 company. Henry is currently a non-Executive Director of NASDAQ-quoted BMC (Building Materials Corp) [NASDAQ:BMCH] which has sales of US$3.8 billion and a market capitalisation of US$1.6 billion. Henry holds an MBA from Queens University, Kingston, Ontario and has held numerous executive level positions both in North America and also the United Kingdom.
Joseph is a qualified Chartered Accountant with significant management consulting experience. Before joining Sativa, Joseph was a Director of Consulting at Kantar Consulting, part of WPP plc (“WPP”) which advises Retail, Sales and Shopper clients on enhancing their commercial capability and the commercial competency of their staff.
Prior to this, Joseph was Chief Financial Officer and a senior board member at WPP’s Kantar Futures, which advises its clients on enhancing profit through change and shaping strategy.
Here, Joseph was accountable for financial performance, managing a global finance team. From 2012 – 2015 Joseph was Global Commercial Director of WPP’s Kantar subsidiary Taylor Nelson Sofres, a $1.8 billion turnover marketing agency.
Before joining WPP, Joseph was an Audit Senior at Mazars LLP, where he qualified as an Accountant with the Institute of Chartered Accountants in England and Wales (ICAEW), being made a Fellow in 2018. He gained a Geophysics BSc (Hons) 2:1 from Southampton University.
As at the date of this announcement, Joseph has been granted 3,350,000 share options in the Company at 1.5p.
Jonathan joins as non-Executive Chairman. Jonathan is an experienced, City-based corporate financier, who began his City career after graduating from Cambridge University with a M.A. in Economics. He was Chairman of Ideagen plc on its admission to the AIM market in July 2012 until April 2018 and remains a non-Executive Director. Following eight years in Citibank London’s corporate banking division, providing debt finance for growth and acquisition purposes, he moved to Citicorp’s London investment bank (CIBL) where, as a Director in the Corporate Finance Department, he worked on both UK and cross-border transactions.
Geremy Thomas, Deputy Chairman, is a serial entrepreneur with a successful track record in the telecommunication, e-learning and consumer finance industries. Geremy co-founded The Carphone Group Plc in the late 1980’s and grew the business to exceed 10% market share before selling to Cable & Wireless for £16m. This was followed by the creation and listing of PNC Telecom Plc, a telecoms business that at its peak was valued at over £200m. In 2001 Geremy co-founded TMTI Ltd. TMTI is a highly profitable technical support business which works with the major brands in enhancing the customer experience. George Banco ltd, a consumer Finance business started by Thomas in 2013, was recently sold to Non Standard Finance Plc for £53m. Other business interests include Carbon Managers ltd an environmental services consultancy company.
Angus is an adviser and capital markets professional with nearly 25 years’ experience in global banking with specific expertise in strategic and equity advisory, M&A and ECM. He has held, inter alia, managing director and management roles covering advisory, equity advisory and ECM at a number of organisations, including head of Mid-Market Advisory and Broking at Credit Suisse and head of UK ECM Dresdner Kleinwort. He has a long track record of advising companies and high profile individuals in the UK, USA and Europe.
He is currently a Senior Advisor at Zeus Capital, the independent investment bank, and is also Chairman of North Berwick SA, a business that consolidates portfolios of company-owned life insurance, and of the advisory board of Luxon Payments Ltd, a company using block chain distributed ledger technology to create a global electronic wallet.
Prior to his career in finance Angus was an Army Officer. Angus has a BA (Hons) in Politics and International Relations from the University of Reading.
Mark Blower, non-Executive Director, is an experienced finance professional, having spent the last 20 years actively overseeing the financial performance of over 70 UK SME’s, with a particular focus on raising debt and private equity. He began his career in 1996 at the Investment Banking division of a large UK bank, before joining NM Rothschild in 2000. He then ran a highly successful leveraged debt team for another UK lending institution for five years before starting his Private Equity career in 2010. During his career to-date he has held a number of board positions, across a variety of sectors.
Anne is an experienced Accountant, Company Secretary, and business Mentor who has worked in a range of sectors to achieve business turnaround, growth and development.
Anne has worked as an Executive and Non-Executive Director as well as advising board members in financial and governance matters as the Company Secretary or external consultant.
Dr Horniman has thirty years’ experience in the veterinary industry, including setting up and running a group of private veterinary practices. In addition to this, he worked with corporate practices as a veterinary surgeon and consultant and has worked with online veterinary pharmacies and prescription software companies.
Nick will implement the Company’s licencing strategy through its continuing relationships with the relevant UK agencies and research centres surrounding the complex regulation of the cultivation of cannabis.
Dr Brown is an award-winning Consultant at The Royal Marsden Hospital specialising in pain medicine and anaesthetics and has recently published research into using cannabinoids for cancer pain treatment. Dr Brown holds an honorary research position at the Institute of Cancer Research having completed doctoral research into cancer-related pain at the insitution, becoming the first anaesthetist to complete a higher degree in the Institute’s history.
Dr. Peter Feldschreiber is dually qualified as a barrister and physician. He specialises in medical and healthcare law including medical products liability, pharmaceutical and medical devices regulatory law, clinical negligence and personal injury and medically related employment litigation.
Casework includes the Aspirin Reyes Syndrome product liability litigation, Atomic Veterans Litigation, the morning after pill litigation, the Seroquel litigation, Foetal Anti- convulsant Syndrome Litigation, Cochlear Implants and Cardiac Stent Litigations and judicial review and references to the ECJ on pharmaceutical regulatory issues. He has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Medicines and Healthcare products Regulatory Agency, Department of Health.
Dr Feldschreiber is General Editor of The Law and Regulation of Medicines (Oxford University Press) and is Consultant Editor for the Volume on Medical Products for Halsburys Laws of England and the Lexis Nexis series on updates of UK and European Law. He is co-author of the chapter on the regulation of healthcare products in Butterworths Healthcare Law and Practice. Peter is also the Visiting Senior Lecturer in Pharmaceutical Science at Kings College London.
He is retained counsel to a number of solicitors and has experience of international litigation regarding drug induced injury. He has also published extensively on the law of causation and European regulatory procedure. He has published research into the repair of DNA following ionising radiation whilst working at the Institute of Cancer Research. He is also a member of the Expert Witness Institute.
Clive Page is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease, and he has published over 300 scientific papers and book chapters.
Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of Babraham Biotechnology Ltd, as well as being a Trustee of the Babraham Institute in Cambridge and a Trustee of the Fraunhofer Institute of Toxicology and Experimental Medicine in Hannover. Clive is a Non Executive Director on the Board of ImmuneRegulation Ltd, PreP Biopharma and EpiEndo. Clive started his early career in the Pharmaceutical Industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both Pharmaceutical and Biotech companies. Clive has previously held Non Executive Board positions at Cardiome in Canada and Stirling Products Ltd in Perth, Australia.
Clive is a recent former Chairman of the Animal Science Group of the Royal Society of Biology and has contributed widely to the public debate about the use of animals in Research.
He was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Society of Biology President’s Medal in 2012 for “Outstanding Contributions to the Life Sciences”. He is a Fellow of the Royal Society of Biology and an Honorary Fellow of the British Pharmacological Society. Clive was awarded an OBE for “Services to Pharmacology” in 2017.